Trial Profile

A phase 2 Clinical trial of INB-100

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INB-100 (Primary)
Indications Leukaemia; Myelodysplastic syndromes
Focus Registrational; Therapeutic Use

Most Recent Events

13 Mar 2025 According to an IN8bio media release, company is advancing preparations for potential registrational Phase 2 trial with possible IND submission anticipated in 2026 based on receipt of additional funding.
01 Oct 2024 According to an IN8bio media release, company will also seek to add a parallel control cohort to prospectively assess leukemia patients and enable comparison between patients receiving INB-100 to those who only receive standard haplotransplantation.
12 Aug 2024 According to an IN8bio media release, following FDA type B meeting the company plans to submit an Investigational New Drug (IND) application to the FDA in Q1 2025 and initiate trial in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com